In the quest to control cancer we now face the challenge of translating our increasing insights into the cancer-immunity cycle into more effective immune therapies.
Last month’s American Society of Clinical Oncology (ASCO) meeting kicked off with a presentation from Professor Ruth Plummer, a medical oncologist from Newcastle in the UK who, in 2003, was
With the American Society of Clinical Oncology (ASCO) conference over for another year, Richard Staines presents a round-up of the most significant developments at this year’s event.
Kantar analyst Katie Stockstill discusses the results of phase 3 SOPHIA trial that were presented on the last day of ASCO 2019. MacroGenics' trial compared its margetuximab candida
Sometimes interesting stories from the ASCO conference are the phase I data that generates hope for the future. One such story at ASCO 2019 was the data on Amgen’s KRAS
Exclusive live coverage from day five of the American Society of Clinical Oncology's annual meeting in Chicago. • To view all of our coverage from the preeminent cancer event, prod
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.